Genelux (GNLX) Competitors $3.58 -0.20 (-5.29%) Closing price 04:00 PM EasternExtended Trading$3.60 +0.02 (+0.45%) As of 07:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends GNLX vs. IMTX, PGEN, MAZE, GHRS, CGEM, AUTL, ABVX, DNA, CMRX, and KROSShould you be buying Genelux stock or one of its competitors? The main competitors of Genelux include Immatics (IMTX), Precigen (PGEN), Maze Therapeutics (MAZE), GH Research (GHRS), Cullinan Therapeutics (CGEM), Autolus Therapeutics (AUTL), ABIVAX Société Anonyme (ABVX), Ginkgo Bioworks (DNA), Chimerix (CMRX), and Keros Therapeutics (KROS). These companies are all part of the "pharmaceutical products" industry. Genelux vs. Immatics Precigen Maze Therapeutics GH Research Cullinan Therapeutics Autolus Therapeutics ABIVAX Société Anonyme Ginkgo Bioworks Chimerix Keros Therapeutics Genelux (NASDAQ:GNLX) and Immatics (NASDAQ:IMTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their community ranking, risk, institutional ownership, dividends, analyst recommendations, valuation, media sentiment, profitability and earnings. Which has stronger valuation & earnings, GNLX or IMTX? Genelux has higher earnings, but lower revenue than Immatics. Immatics is trading at a lower price-to-earnings ratio than Genelux, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenelux$8K15,455.76-$28.30M-$0.95-3.77Immatics$115.50M4.67-$104.98M-$0.66-6.85 Does the media favor GNLX or IMTX? In the previous week, Immatics had 3 more articles in the media than Genelux. MarketBeat recorded 4 mentions for Immatics and 1 mentions for Genelux. Genelux's average media sentiment score of 0.94 beat Immatics' score of 0.60 indicating that Genelux is being referred to more favorably in the media. Company Overall Sentiment Genelux Positive Immatics Positive Which has more volatility and risk, GNLX or IMTX? Genelux has a beta of -1.41, meaning that its share price is 241% less volatile than the S&P 500. Comparatively, Immatics has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. Is GNLX or IMTX more profitable? Genelux has a net margin of 0.00% compared to Immatics' net margin of -47.94%. Immatics' return on equity of -15.90% beat Genelux's return on equity.Company Net Margins Return on Equity Return on Assets GeneluxN/A -105.05% -80.16% Immatics -47.94%-15.90%-9.38% Do institutionals & insiders have more ownership in GNLX or IMTX? 37.3% of Genelux shares are held by institutional investors. Comparatively, 64.4% of Immatics shares are held by institutional investors. 9.3% of Genelux shares are held by company insiders. Comparatively, 3.3% of Immatics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in GNLX or IMTX? Immatics received 16 more outperform votes than Genelux when rated by MarketBeat users. However, 100.00% of users gave Genelux an outperform vote while only 75.00% of users gave Immatics an outperform vote. CompanyUnderperformOutperformGeneluxOutperform Votes14100.00% Underperform VotesNo VotesImmaticsOutperform Votes3075.00% Underperform Votes1025.00% Do analysts recommend GNLX or IMTX? Genelux currently has a consensus target price of $18.25, indicating a potential upside of 409.78%. Immatics has a consensus target price of $16.67, indicating a potential upside of 268.73%. Given Genelux's higher probable upside, analysts plainly believe Genelux is more favorable than Immatics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Genelux 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20Immatics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 SummaryGenelux and Immatics tied by winning 8 of the 16 factors compared between the two stocks. Remove Ads Get Genelux News Delivered to You Automatically Sign up to receive the latest news and ratings for GNLX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GNLX vs. The Competition Export to ExcelMetricGeneluxPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$123.65M$6.92B$5.61B$7.93BDividend YieldN/A2.72%4.89%4.05%P/E Ratio-3.776.1123.5218.73Price / Sales15,455.76223.52371.97119.64Price / CashN/A65.6738.0534.64Price / Book4.906.616.844.19Net Income-$28.30M$139.99M$3.19B$246.99M7 Day Performance-4.02%-2.46%5.28%-2.84%1 Month Performance-34.43%-9.02%-1.08%-10.76%1 Year Performance-44.41%-5.12%12.28%0.49% Genelux Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GNLXGenelux1.536 of 5 stars$3.58-5.3%$18.25+409.8%-43.9%$123.65M$8,000.00-3.7710Gap UpIMTXImmatics2.0794 of 5 stars$4.18-4.6%$16.67+298.7%-62.1%$498.91M$115.50M-6.33260PGENPrecigen3.7674 of 5 stars$1.67-3.5%$7.00+319.2%+18.3%$489.09M$3.96M-3.04190Upcoming EarningsPositive NewsMAZEMaze TherapeuticsN/A$11.04-9.7%$25.67+132.5%N/A$483.30M$167.50M0.00121Quiet Period ExpirationGHRSGH Research2.9503 of 5 stars$9.21-9.1%$30.60+232.2%+22.7%$479.18MN/A-11.6610Analyst ForecastNews CoverageHigh Trading VolumeCGEMCullinan Therapeutics2.2756 of 5 stars$8.00-5.8%$32.50+306.3%-46.4%$465.82MN/A-2.8230AUTLAutolus Therapeutics3.1386 of 5 stars$1.75+1.2%$10.40+494.3%-63.3%$465.66M$10.09M-1.45330Upcoming EarningsPositive NewsABVXABIVAX Société Anonyme1.9313 of 5 stars$7.33-4.6%$38.67+427.5%-53.4%$464.47MN/A0.0061DNAGinkgo Bioworks0.8683 of 5 stars$8.04-2.4%$4.58-43.1%N/A$462.13M$227.04M-0.611,218Positive NewsCMRXChimerix2.634 of 5 stars$5.04-4.0%$9.00+78.6%+616.9%$453.28M$159,000.00-5.3690High Trading VolumeKROSKeros Therapeutics3.0409 of 5 stars$11.10+0.2%$42.33+281.4%-82.6%$449.63M$3.55M-2.13100Positive News Remove Ads Related Companies and Tools Related Companies Immatics Alternatives Precigen Alternatives Maze Therapeutics Alternatives GH Research Alternatives Cullinan Therapeutics Alternatives Autolus Therapeutics Alternatives ABIVAX Société Anonyme Alternatives Ginkgo Bioworks Alternatives Chimerix Alternatives Keros Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GNLX) was last updated on 3/13/2025 by MarketBeat.com Staff From Our Partners$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredBuy NVDA Now? After weeks of volatility, did President Trump just turn Nvidia (NVDA) into a raging BUY? The beloved chip...Chaikin Analytics | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genelux Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Genelux With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
